Free tool
FAERS Monitor: Norditropin Flexpro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 021148 or its brand name (Norditropin Flexpro, Somatropin). Reports on generic versions are filed under their own applications.
Reports
9,514
Serious
6,529
69% of reports
Hospitalization
2,552
Death reported
504
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use555
- headache406
- device leakage347
- injection site pain302
- fatigue262
- drug dose omission by device233
- drug ineffective233
- death204
- pyrexia202
- product dose omission issue187
- vomiting185
- nausea184
- arthralgia178
- condition aggravated162
- seizure161
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 67 |
| 2005 | 35 |
| 2006 | 44 |
| 2007 | 149 |
| 2008 | 99 |
| 2009 | 276 |
| 2010 | 216 |
| 2011 | 253 |
| 2012 | 297 |
| 2013 | 145 |
| 2014 | 257 |
| 2015 | 371 |
| 2016 | 551 |
| 2017 | 477 |
| 2018 | 553 |
| 2019 | 726 |
| 2020 | 658 |
| 2021 | 545 |
| 2022 | 743 |
| 2023 | 991 |
| 2024 | 879 |
| 2025 | 672 |
| 2026 | 510 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,645 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device leakageSignal | 347 | 17.8 | 16.1 | 5,462 |
| drug dose omission by deviceSignal | 233 | 6.6 | 5.8 | 1,101 |
| seizureSignal | 161 | 3.1 | 2.6 | 226 |
| injection site painSignal | 302 | 2.2 | 1.9 | 194 |
| headache | 406 | 1.4 | 1.3 | 54 |
| product dose omission issue | 187 | 1.4 | 1.2 | 22 |
| off label use | 555 | 1.4 | 1.3 | 66 |
| pyrexia | 202 | 1.3 | 1.1 | 13 |
| condition aggravated | 162 | 1.2 | 1.0 | 4 |
| arthralgia | 178 | 0.9 | 0.8 | 0 |
| vomiting | 185 | 0.9 | 0.8 | 4 |
| fatigue | 262 | 0.7 | 0.7 | 24 |
| death | 204 | 0.5 | 0.5 | 92 |
| nausea | 184 | 0.5 | 0.4 | 87 |
| drug ineffective | 233 | 0.4 | 0.3 | 235 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.